Cancer Gene Therapy

Wild-Type p53 Expression Reduces Tumorigenicity in a Variety of Cancers

Published in Gene Therapy Weekly, April 29th, 1996

Restoration of wild-type p53 gene expression by retroviral or adenoviral vectors reduces the tumorigenicity of cancers with mutant p53.

S. Kagawa et al. submitted data at the 87th annual meeting of the American Association for Cancer Research, held April 20-24, 1996, in Washington D.C. which showed the potential of viral-mediated gene therapy against a variety of cancers (abstract "Recombinant Virus-Mediated Transfer of the Wild-Type p53 Gene is a Potent Therapeutic Strategy against Various Types of Human Cancer).

"We examined the in vitro and in vivo antitumor effect of wild-type p53 (wt-p53)-expressing viral...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1996-04-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry